Abdominal Aortic Aneurysms - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Abdominal Aortic Aneurysms - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Abdominal Aortic Aneurysms - Pipeline Review, H1 2015', provides an overview of the Abdominal Aortic Aneurysms's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Abdominal Aortic Aneurysms, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal Aortic Aneurysms and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Abdominal Aortic Aneurysms
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Abdominal Aortic Aneurysms and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Abdominal Aortic Aneurysms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Abdominal Aortic Aneurysms pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Abdominal Aortic Aneurysms
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Abdominal Aortic Aneurysms pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abdominal Aortic Aneurysms Overview 6
Therapeutics Development 7
Pipeline Products for Abdominal Aortic Aneurysms - Overview 7
Pipeline Products for Abdominal Aortic Aneurysms - Comparative Analysis 8
Abdominal Aortic Aneurysms - Therapeutics under Development by Companies 9
Abdominal Aortic Aneurysms - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Abdominal Aortic Aneurysms - Products under Development by Companies 13
Abdominal Aortic Aneurysms - Companies Involved in Therapeutics Development 14
AstraZeneca Plc 14
Carolus Therapeutics, Inc. 15
Eli Lilly and Company 16
Novartis AG 17
Abdominal Aortic Aneurysms - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BSN-908 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
canakinumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CT-2009 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LY-3000328 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ticagrelor - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Abdominal Aortic Aneurysms - Recent Pipeline Updates 38
Abdominal Aortic Aneurysms - Dormant Projects 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for Abdominal Aortic Aneurysms, H1 2015 7
Number of Products under Development for Abdominal Aortic Aneurysms - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Comparative Analysis by Unknown Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Abdominal Aortic Aneurysms - Pipeline by AstraZeneca Plc, H1 2015 14
Abdominal Aortic Aneurysms - Pipeline by Carolus Therapeutics, Inc., H1 2015 15
Abdominal Aortic Aneurysms - Pipeline by Eli Lilly and Company, H1 2015 16
Abdominal Aortic Aneurysms - Pipeline by Novartis AG, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Abdominal Aortic Aneurysms Therapeutics - Recent Pipeline Updates, H1 2015 38
Abdominal Aortic Aneurysms - Dormant Projects, H1 2015 47